HUCH Comprehensive Cancer Center, building 2

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Lung cancer1 trial
• Sarcoma1 trial

Phase

• Phase 11 trial
• Phase 2/31 trial

Status

• Completed2 trials

Lead sponsor

• Boehringer Ingelheim2 trials

Closed trials

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

  NCT03099174· Phase 1· Boehringer Ingelheim· Source